Cencora (NYSE:COR) Downgraded to Hold Rating by Wall Street Zen

Wall Street Zen lowered shares of Cencora (NYSE:COR) from a buy rating to a hold rating in a research note released on Friday morning.

Other analysts also recently issued reports about the stock. Weiss Ratings reissued a “buy (b-)” rating on shares of Cencora in a research report on Tuesday. Robert W. Baird increased their price target on shares of Cencora from $355.00 to $395.00 and gave the company an “outperform” rating in a report on Thursday, November 6th. Evercore ISI set a $400.00 price target on shares of Cencora and gave the company an “outperform” rating in a research report on Thursday, November 6th. TD Cowen boosted their price objective on shares of Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a report on Monday, November 10th. Finally, JPMorgan Chase & Co. increased their target price on Cencora from $344.00 to $417.00 and gave the company an “overweight” rating in a research note on Tuesday, November 11th. Nine investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $371.09.

Cencora Stock Up 0.1%

COR stock opened at $368.93 on Friday. The business has a 50 day moving average of $335.71 and a 200 day moving average of $307.44. The firm has a market cap of $71.53 billion, a PE ratio of 37.96, a price-to-earnings-growth ratio of 1.56 and a beta of 0.63. Cencora has a twelve month low of $223.92 and a twelve month high of $377.54. The company has a quick ratio of 0.53, a current ratio of 0.90 and a debt-to-equity ratio of 3.64.

Cencora (NYSE:COR) last released its earnings results on Wednesday, November 5th. The company reported $3.84 EPS for the quarter, topping analysts’ consensus estimates of $3.79 by $0.05. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The firm had revenue of $83.73 billion for the quarter, compared to analysts’ expectations of $83.36 billion. During the same period in the prior year, the firm posted $3.34 earnings per share. The company’s quarterly revenue was up 5.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. On average, research analysts forecast that Cencora will post 15.37 EPS for the current fiscal year.

Cencora Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 14th will be paid a dividend of $0.60 per share. The ex-dividend date is Friday, November 14th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.7%. This is an increase from Cencora’s previous quarterly dividend of $0.55. Cencora’s dividend payout ratio is presently 30.19%.

Insider Activity

In other news, CEO Robert P. Mauch sold 5,096 shares of the company’s stock in a transaction dated Tuesday, November 18th. The shares were sold at an average price of $366.64, for a total transaction of $1,868,397.44. Following the completion of the sale, the chief executive officer owned 65,746 shares of the company’s stock, valued at $24,105,113.44. This represents a 7.19% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Chairman Steven H. Collis sold 31,350 shares of the firm’s stock in a transaction that occurred on Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the completion of the transaction, the chairman directly owned 305,913 shares in the company, valued at approximately $88,671,942.18. The trade was a 9.30% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 46,640 shares of company stock valued at $14,099,338 in the last ninety days. Insiders own 10.80% of the company’s stock.

Hedge Funds Weigh In On Cencora

A number of institutional investors have recently bought and sold shares of the stock. Voleon Capital Management LP bought a new stake in Cencora in the 1st quarter worth approximately $3,111,000. Baader Bank Aktiengesellschaft raised its stake in shares of Cencora by 318.5% in the second quarter. Baader Bank Aktiengesellschaft now owns 4,336 shares of the company’s stock valued at $1,300,000 after acquiring an additional 3,300 shares during the period. Focus Partners Wealth lifted its stake in Cencora by 25.8% in the first quarter. Focus Partners Wealth now owns 5,715 shares of the company’s stock worth $1,589,000 after purchasing an additional 1,171 shares during the last quarter. Acadian Asset Management LLC lifted its stake in shares of Cencora by 947.5% during the 2nd quarter. Acadian Asset Management LLC now owns 257,082 shares of the company’s stock worth $77,069,000 after acquiring an additional 232,539 shares during the last quarter. Finally, Martin Capital Partners LLC boosted its stake in shares of Cencora by 205.2% during the second quarter. Martin Capital Partners LLC now owns 3,784 shares of the company’s stock valued at $1,135,000 after purchasing an additional 2,544 shares during the period. 97.52% of the stock is owned by institutional investors.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.